HCPCS J1290 is officially defined as "Injection, ecallantide, 1 mg." HCPCS J1290 is referenced in 5 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Blue Cross & Blue Shield of Mississippi, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J1290 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of North Dakota's August 2026 pharmacy update covers Medicaid Expansion medical drug prior authorization policies, with new policies and coding changes effective October 1, 2026. The most important billing change is the new HCPCS codes that replace older codes, such as Q5172 for Filkri and J9362 for Yondelis, plus added diagnosis codes for several drugs; the commercial pharmacy policies were reviewed with no changes listed.
Effective 04/01/2026, the BCBSMS hereditary angioedema policy added Andembry (garadacimab-gxii), Dawnzera (donidalorsen), and Ekterly (sebetralstat) to its list of drugs, and Sajazir (icatibant) was added effective the same date. The revised criteria cover documentation of recurrent angioedema episodes and HAE subtype, and add separate criteria for acute attack treatment and for routine prophylaxis. Dawnzera and Ekterly are considered not medically necessary because other formulary alternatives are covered by the Plan for both acute and prophylactic treatment of HAE attacks.
Aetna Clinical Policy Bulletin 0782 sets the criteria for hereditary angioedema (HAE) drugs under commercial medical plans, and precertification is required for these agents in applicable plan designs. Cinryze, Dawnzera, Haegarda and Takhzyro are considered medically necessary for prevention of HAE attacks when they are prescribed by or in consultation with a prescriber who specializes in the management of HAE, are not used in combination with another prophylaxis medication, and the member meets the initial criteria, including C1 inhibitor deficiency confirmed by laboratory testing or a normal C1 inhibitor with a qualifying pathogenic variant or a family history of angioedema refractory to high-dose antihistamine therapy for at least one month. Berinert is considered medically necessary for treatment of acute attacks only when the member has a contraindication, intolerance or ineffective response to the equivalent alternative Ruconest, tried for one month, and all other indications of these agents are considered experimental, investigational or unproven.
Aetna Clinical Policy Bulletin 0782 covers hereditary angioedema (HAE) agents for commercial medical plans. Precertification of HAE agents is required of all Aetna participating providers and members in applicable plan designs. Aetna considers prophylactic HAE agents medically necessary when the drug is prescribed by or in consultation with a prescriber who specializes in HAE management, is not used in combination with other HAE prophylaxis, and the member meets the C1 inhibitor criteria at diagnosis with other causes of angioedema ruled out. Berinert is considered medically necessary for acute attacks only for members with a contraindication, intolerance or ineffective response to Ruconest after a one-month trial. Continuation of prophylaxis requires a significant reduction in attack frequency (for example, at least 50 percent) and reduced use of medications for acute attacks.
Berinert (human c1-esterase inhibitor) may be considered medically necessary for hereditary angioedema when all of the listed diagnosis, medication review and specialist criteria are met. Cinryze (human c1-esterase inhibitor), Kalbitor (ecallantide), Ruconest (recombinant c1-esterase inhibitor) and Takhzyro (lanadelumab-flyo) are considered not medically necessary because other formulary alternatives are covered for both acute and prophylactic treatment of HAE attacks. The 04/01/2026 revision set Berinert quantity limits of 20 units/kg per infusion, up to 2 doses per 30 days, changed the initial approval length from 6 months to 12 months, and updated the renewal criteria.
Watch J1290
Get one email when a payer policy names J1290, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J1290
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J1290 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.